Home | Investors | ASX Announcements | 2018 ASX Announcements 2018 Date Document 11/12/2018 Response to ASX Price and Volume Query 03/12/2018 FDA Clearance Granted for FerriSmart 20/11/2018 R&D Tax Incentive 16/11/2018 Change of Director's Interest Notice 08/11/2018 Results of Meeting 08/11/2018 AGM Presentation 31/10/2018 New Work Order to provide services for Clinical Trial 29/10/2018 Appendix 4C - quarterly 23/10/2018 Response to ASX Price and Volume Query 23/10/2018 Pause in Trading 08/10/2018 Notice of Annual General Meeting/Proxy Form 08/10/2018 Annual Report to shareholders 14/09/2018 Amended Appendix 3B 13/09/2018 Appendix 4G and Corporate Governance Statement 13/09/2018 Full Year Statutory Accounts 13/09/2018 Appendix 3B 06/09/2018 Change of Substantial Shareholder Notification 06/09/2018 Change of Director's Interest Notice 30/08/2018 Preliminary Final Report 27/08/2018 Additional Information on Announcement Dated 23 August 2018 27/08/2018 Trading Halt 23/08/2018 Resonance Health contracted for two new clinical trials 23/07/2018 Appendix 4C - quarterly 11/07/2018 TGA, CE Mark clearance for A.I. Solution FerriSmart 05/07/2018 Alliance Partner Agreement with Blackford Analysis 29/06/2018 Customer Newsletter - June 2018 12/06/2018 Investor Presentation June 2018 31/05/2018 Change of Director's Interest Notice 29/05/2018 Change of Director's Interest Notice 04/05/2018 Additional Info. in relation to 4 May 2018 announcement 04/05/2018 Resonance Deal to distribute Diabetic Retinopathy AI tool 23/04/2018 Appendix 4C - quarterly 23/03/2018 Customer Newsletter - March 2018 09/03/2018 Appendix 3B 07/03/2018 Change of Director's Interest Notice 28/02/2018 Director Appointment 26/02/2018 Half Yearly Report and Accounts 23/02/2018 Appointment of CEO 20/02/2018 RHT Develops new assessment for the screening of NASH 15/02/2018 Change of Director's Interest Notice 13/02/2018 Resonance Health contracted for new clinical trial 09/02/2018 R&D Tax Incentive 31/01/2018 Appendix 4C - quarterly 12/01/2018 FerriScan contracted for two new Clinical Trials